SMC kicks off the new year by accepting five new medicines for NHS use
Darzalex, Rozlytrek and Tavlesse among newly accepted drugs
Read More
Tag: Rozlytrek
Roche’s tumour-agnostic therapy Rozlytrek approved in EU
Therapy has been approved to treat advanced NTRK fusion-positive solid tumours
Read More
NICE backs Rozlytrek for subset of NSCLC patients
Rozlytrek is one of a new group of histology-independent cancer treatments designed to treat tumours regardless of where the primary tumour originates
Read More
New vaccine for Ebola among CHMP recommendations
The vaccine could be Janssen’s first to win EU approval
Read More
Rozlytrek bags FDA approval
For the indication of ROS1-positive, metastatic non-small cell lung cancer (NSCLC).
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
